Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

18.85 -0.14 (-0.74%)

Streaming Delayed Price Updated: 10:48 AM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Volume	80,879
Open	19.24
Bid (Size)	18.78 (200)
Ask (Size)	18.92 (300)
Prev. Close	18.99
Today's Range	18.62 - 19.51
52wk Range	12.56 - 26.30
Shares Outstanding	54,902,942
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 20, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

February 20, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Performance

YTD	+40.8%	+40.8%
1 Month	+31.6%	+31.6%
3 Month	+41.4%	+41.4%
6 Month	+11.5%	+11.5%
1 Year	+0.5%	+0.5%

More News

Pulse Biosciences Inc (NASDAQ:PLSE) Narrows Q4 Loss, Beats Revenue Estimates ↗

February 19, 2026

Via Chartmill

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

February 19, 2026

From Pulse Biosciences, Inc.

Via Business Wire

These stocks have an unusual volume in today's session ↗

February 12, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

These stocks are moving in today's session ↗

February 06, 2026

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

February 06, 2026

Via Chartmill

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

February 05, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

February 04, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

February 03, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

January 09, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

January 06, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

December 18, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

December 09, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

November 06, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences (PLSE) Earnings Transcript ↗

November 06, 2025

Via The Motley Fool

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

November 05, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

October 24, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

October 22, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 16, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

October 10, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Frequently Asked Questions

Is Pulse Biosciences, Inc - Common Stock publicly traded?

Yes, Pulse Biosciences, Inc - Common Stock is publicly traded.

What exchange does Pulse Biosciences, Inc - Common Stock trade on?

Pulse Biosciences, Inc - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Pulse Biosciences, Inc - Common Stock?

The ticker symbol for Pulse Biosciences, Inc - Common Stock is PLSE on the Nasdaq Stock Market

What is the current price of Pulse Biosciences, Inc - Common Stock?

The current price of Pulse Biosciences, Inc - Common Stock is 18.85

When was Pulse Biosciences, Inc - Common Stock last traded?

The last trade of Pulse Biosciences, Inc - Common Stock was at 02/25/26 10:48 AM ET

What is the market capitalization of Pulse Biosciences, Inc - Common Stock?

The market capitalization of Pulse Biosciences, Inc - Common Stock is 1.03B

How many shares of Pulse Biosciences, Inc - Common Stock are outstanding?

Pulse Biosciences, Inc - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.